Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News iCo Therapeutics V.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:MSCL)

Fundamentals Snapshot (TSXV:MSCL)

Opinion & Analysis (TSXV:MSCL)

No current opinion is available.

Bullboard Posts (TSXV:MSCL)

RE:RE:.018 per share pre-consolidation nice

And they didn't even last a year before they start diluting us! Unreal!
beenthere - July 17, 2022

RE:RE:.018 per share pre-consolidation nice

Let's see what the preliminary short form prospectus will bring forth, if it does close on July 28, 2022?  G1945V
G1945V - July 15, 2022

RE:.018 per share pre-consolidation nice

Sure has been, market isn't helping right now but it really didn't seem like they were ready to go public and overestimated...
Itistoo - July 14, 2022

.018 per share pre-consolidation nice

  What a joke this company is, azzclowns running this POS.
Drambuey - July 13, 2022

Defeat Duchenne Canada

https://musculardystrophynews.com/2022/06/16/defeat-duchenne-canada-grants-1m-dmd-treatment-research/ Defeat Duchenne Canada grant...
db2067 - July 4, 2022

Patent

Satellos Co-founder and CSO, Dr. Michael Rudnicki, a co-inventor, noted, "this new patent application represents the culmination...
db2067 - July 4, 2022